Terns Pharmaceuticals, Inc.
NASDAQ:TERN
7.06 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 0 | 0 | 1.322 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue
| 0.24 | 0.236 | 0.22 | 0.222 | 0.217 | 0.222 | 0.485 | 0.252 | 0.269 | 0.278 | 0.114 | 0.107 | 0.119 | 0.172 | 0 | 0 | 0 | 0 | 0 |
Gross Profit
| -0.24 | -0.236 | 1.102 | -0.222 | -0.217 | -0.222 | -0.485 | -0.252 | -0.269 | -0.278 | 0.886 | -0.107 | -0.119 | -0.172 | 0 | 0 | 0 | 0 | 0 |
Gross Profit Ratio
| 0 | 0 | 0.834 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.886 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Reseach & Development Expenses
| 18.352 | 18.587 | 17.459 | 14.831 | 14.151 | 17.056 | 10.658 | 12.161 | 8.662 | 8.136 | 9.462 | 7.153 | 5.961 | 8.735 | 7.77 | 5.404 | 7.611 | 7.244 | 7.556 |
General & Administrative Expenses
| 7.185 | 6.859 | 6.599 | 18.353 | 7.008 | 7.101 | 6.17 | 5.131 | 5.422 | 5.689 | 5.416 | 4.715 | 4.857 | 4.561 | 0.998 | 3.333 | 2.486 | 2.179 | 2.388 |
Selling & Marketing Expenses
| -0.24 | -0.236 | -0.22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 6.945 | 6.623 | 6.379 | 18.353 | 7.008 | 7.101 | 6.17 | 5.131 | 5.422 | 5.689 | 5.416 | 4.715 | 4.857 | 4.561 | 0.998 | 3.333 | 2.486 | 2.179 | 2.388 |
Other Expenses
| -0.014 | -0.012 | -0.245 | -0.005 | -0.06 | -0.004 | -0.004 | -0.014 | -0.054 | 0.004 | 0.01 | 0.004 | 0.039 | -0.013 | -0.747 | -2.753 | 0.25 | 0.167 | 0.139 |
Operating Expenses
| 25.297 | 25.21 | 23.838 | 33.184 | 21.159 | 24.157 | 16.828 | 17.292 | 14.084 | 13.825 | 14.878 | 11.868 | 10.818 | 13.296 | 8.768 | 8.737 | 10.097 | 9.423 | 9.944 |
Operating Income
| -25.537 | -25.446 | -24.058 | -33.184 | -21.159 | -24.157 | -16.828 | -17.292 | -14.084 | -13.825 | -13.878 | -11.868 | -10.818 | -13.296 | -8.768 | -8.737 | -10.097 | -9.423 | -9.944 |
Operating Income Ratio
| 0 | 0 | -18.198 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -13.878 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Other Income Expenses Net
| 2.862 | 3.17 | 3.088 | -0.005 | -0.06 | 2.689 | 1.324 | 0.485 | 0.16 | 0.073 | 0.01 | 0.004 | 0.039 | -0.013 | -0.452 | -2.753 | 0.25 | 0.167 | -0.207 |
Income Before Tax
| -22.675 | -22.276 | -20.97 | -29.709 | -17.824 | -21.468 | -15.504 | -16.807 | -13.924 | -13.752 | -13.813 | -11.815 | -10.724 | -13.298 | -9.218 | -11.489 | -9.845 | -9.206 | -10.044 |
Income Before Tax Ratio
| 0 | 0 | -15.862 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -13.813 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Income Tax Expense
| 0.061 | 0.097 | 0.049 | 0.058 | 0.072 | 0.06 | 0.318 | 0.013 | 0.006 | 0.021 | 0.435 | 0.02 | 0.014 | 0.039 | 0.711 | 0.102 | -0.159 | -0.255 | 0.002 |
Net Income
| -22.736 | -22.373 | -21.019 | -29.767 | -17.896 | -21.528 | -15.822 | -16.82 | -13.93 | -13.773 | -14.248 | -11.835 | -10.738 | -13.337 | -9.929 | -11.435 | -9.688 | -9.001 | -9.775 |
Net Income Ratio
| 0 | 0 | -15.899 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -14.248 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS
| -0.31 | -0.3 | -0.29 | -0.42 | -0.25 | -0.31 | -0.29 | -0.44 | -0.55 | -0.55 | -0.56 | -0.47 | -0.43 | -0.88 | -0.65 | -0.48 | -0.4 | -0.38 | -0.41 |
EPS Diluted
| -0.31 | -0.3 | -0.29 | -0.42 | -0.25 | -0.31 | -0.29 | -0.44 | -0.55 | -0.55 | -0.56 | -0.47 | -0.43 | -0.88 | -0.65 | -0.48 | -0.4 | -0.38 | -0.41 |
EBITDA
| -25.297 | -25.21 | -23.838 | -32.962 | -20.942 | -24.157 | -16.828 | -17.04 | -13.815 | -13.547 | -13.878 | -11.761 | -10.699 | -13.124 | -8.662 | -8.636 | -9.998 | -9.335 | -9.871 |
EBITDA Ratio
| 0 | 0 | -18.032 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -13.878 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |